W
WAVEMAN · COMPANY
LAB · Standard Biotools Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

LAB

STANDARD BIOTOOLS INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001162194
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
88
13F, latest reported quarter
REVENUE GROWTH
-6.2%
XBRL, annual
NET MARGIN
-87.8%
CONVERSIONS · 180D
2
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
88 funds added or opened last quarter
more than 61% of Pharma & Biotech
REVENUE
-6.2% year over year
below 67% of Pharma & Biotech
MARGIN
-87.8% net margin
below 64% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
0.7% of shares outstanding short · 1.3 days to cover · settled 2026-07-31
below 76% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
88 funds added or opened positions in the latest 13F quarter, of 144 holders.
VIKING GLOBAL INVESTORS LP disclosed a 5%+ stake (15.0%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -46.0%
-46.0%12M
-48%-20%+8%+35%2025-092025-102025-122026-032026-052026-072026-09 2025-11-25 · Casdin Partners GP, LLC bought $9.8M2025-11-20 · Casdin Eli bought $585.0K2025-11-13 · Casdin Partners Master Fund, L.P. bought $540.0K2025-11-19 · Casdin Eli bought $448.0K2025-11-12 · Casdin Partners GP, LLC bought $446.2K2025-11-11 · Casdin Partners GP, LLC bought $360.0K2025-11-18 · Casdin Eli bought $338.2K2025-11-10 · Casdin Partners GP, LLC bought $321.8K2025-09-04 · Casdin Eli bought $320.0K2025-09-03 · Casdin Eli bought $317.5K2025-11-14 · Casdin Partners Master Fund, L.P. bought $310.0K2025-11-17 · Casdin Partners Master Fund, L.P. bought $274.5K2025-11-07 · Casdin Partners GP, LLC bought $252.0K2025-12-04 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $217.5K2025-11-24 · Casdin Partners GP, LLC bought $214.5K2025-12-02 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $177.5K2025-09-09 · Casdin Partners Master Fund, L.P. bought $129.0K2025-12-03 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $108.0K2026-06-12 · VIKING GLOBAL INVESTORS LP filed a 5%+ stake (15.0%)2026-06-12 · Viking Global Opportunities Parent GP LLC filed a 5%+ stake (15.0%)2026-06-12 · Viking Global Opportunities GP LLC filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Portfolio GP LLC filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Illiquid Investments Sub-Master LP filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Drawdown GP LLC filed a 5%+ stake (5.0%)2026-06-12 · Viking Global Opportunities Drawdown Portfolio GP LLC filed a 5%+ stake (5.0%)2026-06-12 · Viking Global Opportunities Drawdown (Aggregator) LP filed a 5%+ stake (5.0%)2026-06-12 · HALVORSEN OLE ANDREAS filed a 5%+ stake (15.0%)2026-06-12 · Shabet Rose Sharon filed a 5%+ stake (15.0%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows 88 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for STANDARD BIOTOOLS INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-04
150,000.0
$217.5K
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-03
75,000.0
$108.0K
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-02
125,000.0
$177.5K
Casdin Partners GP, LLC
Director
BUY
2025-11-25
7,550,000.0
$9.8M
Casdin Partners GP, LLC
Director
BUY
2025-11-24
150,000.0
$214.5K
84 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 79 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Casdin Capital, LLC
88,783,856.0 sh
$73.0M
VIKING GLOBAL INVESTORS LP
58,651,170.0 sh
$48.3M
MAK CAPITAL ONE LLC
28,813,904.0 sh
$23.7M
Long Focus Capital Management, LLC
23,500,000.0 sh
$19.3M
VANGUARD CAPITAL MANAGEMENT LLC
12,252,998.0 sh
$10.1M
5%+ owners
13D = intent to influence · 13G = passive
VIKING GLOBAL INVESTORS LP
ACTIVIST 13D · 2026-06-12
15.0%
Viking Global Opportunities Parent GP LLC
ACTIVIST 13D · 2026-06-12
15.0%
Viking Global Opportunities GP LLC
ACTIVIST 13D · 2026-06-12
10.1%
Viking Global Opportunities Portfolio GP LLC
ACTIVIST 13D · 2026-06-12
10.1%
Viking Global Opportunities Illiquid Investments Sub-Master LP
ACTIVIST 13D · 2026-06-12
10.1%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco NASDAQ Future Gen 200 ETF
$49.8K POSITION · AS OF 2026-02-28
0.4%
Global X Genomics & Biotechnology ETF
$134.8K POSITION · AS OF 2026-02-28
0.3%
Inception Portfolio
$602.0K POSITION · AS OF 2026-03-31
0.3%
Royce Micro-Cap Fund
$793.6K POSITION · AS OF 2026-03-31
0.2%
Royce Capital Fund - Micro-Cap Portfolio
$252.9K POSITION · AS OF 2026-03-31
0.2%
EQ/Morgan Stanley Small Cap Growth Portfolio
$462.9K POSITION · AS OF 2026-03-31
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$85.3M$91.0M$106.3M$97.9M
GROSS PROFIT$42.5M$44.9M$50.5M$37.1M
OPERATING INCOME$-110.2M$-127.5M$-76.6M$-116.2M
NET INCOME$-74.9M$-138.9M$-74.7M$-190.1M
EPS (DILUTED)-0.20-0.52-0.94-2.43
OPERATING CASH FLOW$-74.3M$-143.5M$-43.3M$-89.4M
CASH$120.9M$166.7M$51.7M$81.3M
LONG-TERM DEBT—$299.0K$63.5M$64.9M
BUYBACKS$0$40.5M$5.4M$563.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →